Key Points
- CFO Maged Shenouda purchased 11,665 shares on December 15 at an average price of $4.12 (total ~$48,060), bringing his direct stake to 800,000 shares (a 1.48% ownership increase); he also bought 500,000 shares on November 5 at $2.20 ($1.1M).
- Relmada's stock has been volatile but trading higher (opened $4.50; 12‑month range $0.24–$5.12) with a market cap of about $330M and negative earnings, while analysts are mixed—Mizuho upgraded to outperform and raised its target to $10, leaving the consensus rating at "Hold."
Relmada Therapeutics, Inc. (NASDAQ:RLMD - Get Free Report) CFO Maged Shenouda purchased 11,665 shares of the stock in a transaction that occurred on Monday, December 15th. The shares were purchased at an average price of $4.12 per share, with a total value of $48,059.80. Following the completion of the acquisition, the chief financial officer directly owned 800,000 shares in the company, valued at $3,296,000. The trade was a 1.48% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.
Maged Shenouda also recently made the following trade(s):
- On Wednesday, November 5th, Maged Shenouda acquired 500,000 shares of Relmada Therapeutics stock. The stock was purchased at an average price of $2.20 per share, for a total transaction of $1,100,000.00.
Relmada Therapeutics Trading Up 3.2%
Shares of NASDAQ:RLMD opened at $4.50 on Wednesday. The company has a 50-day moving average price of $3.26 and a 200-day moving average price of $1.78. The company has a market cap of $329.99 million, a price-to-earnings ratio of -2.50 and a beta of 0.74. Relmada Therapeutics, Inc. has a 12 month low of $0.24 and a 12 month high of $5.12.
Relmada Therapeutics (NASDAQ:RLMD - Get Free Report) last released its quarterly earnings results on Thursday, November 13th. The company reported ($0.30) EPS for the quarter, missing analysts' consensus estimates of ($0.04) by ($0.26). As a group, research analysts forecast that Relmada Therapeutics, Inc. will post -2.73 EPS for the current fiscal year.
Institutional Trading of Relmada Therapeutics
Large investors have recently made changes to their positions in the stock. Boothbay Fund Management LLC bought a new position in Relmada Therapeutics during the third quarter valued at approximately $1,393,000. Two Sigma Investments LP raised its stake in Relmada Therapeutics by 82.0% during the 3rd quarter. Two Sigma Investments LP now owns 173,614 shares of the company's stock valued at $349,000 after buying an additional 78,197 shares during the last quarter. AdvisorShares Investments LLC lifted its holdings in shares of Relmada Therapeutics by 1.8% during the 3rd quarter. AdvisorShares Investments LLC now owns 403,488 shares of the company's stock valued at $811,000 after buying an additional 6,974 shares during the period. Corient Private Wealth LLC bought a new position in shares of Relmada Therapeutics during the 2nd quarter valued at $120,000. Finally, LMR Partners LLP purchased a new position in shares of Relmada Therapeutics in the 2nd quarter worth $33,000. 45.24% of the stock is currently owned by institutional investors.
Wall Street Analysts Forecast Growth
Several research analysts have recently issued reports on the stock. Wall Street Zen upgraded shares of Relmada Therapeutics to a "hold" rating in a research note on Saturday, October 11th. Weiss Ratings restated a "sell (e+)" rating on shares of Relmada Therapeutics in a report on Friday, October 31st. Finally, Mizuho upgraded Relmada Therapeutics from a "neutral" rating to an "outperform" rating and increased their target price for the company from $1.00 to $10.00 in a research note on Wednesday, November 19th. One investment analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of "Hold" and an average target price of $10.00.
Read Our Latest Analysis on RLMD
About Relmada Therapeutics
(
Get Free Report)
Relmada Therapeutics, Inc, a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system diseases (CNS) and other disorders in the United States. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a N-methyl-D-aspartate receptor antagonist which is in phase 3 clinical trial for the adjunctive or monotherapy treatment of major depressive disorder.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
